Neuropsychiatric disorders in adults undergoing chimeric antigen receptor T cells therapy for aggressive lymphomas and acute lymphoblastic leukemia.
Leuk Res Rep
; 19: 100364, 2023.
Article
em En
| MEDLINE
| ID: mdl-36873581
ABSTRACT
Objective:
To evaluate risk factors for neuropsychiatric disorders (NPD) in recipients of CART therapy.Methods:
Patients ≥ 18 years with acute lymphoblastic leukemia (ALL), and aggressive B-cell lymphomas who received CART in 2018 were evaluated. Patients with and without NPD were compared.Results:
NPD was diagnosed in 31.2% of patients. Compared to patients without NPD, patients with NPD were likely to be females (P = 0.035) and have ALL (P = 0.039). NPD was significantly associated with female gender (OR = 2.03) and diagnosis of ALL (OR = 2.76). No association between NPD and outcomes.Conclusions:
Female gender and ALL were risk factors for NPD.
ALL, acute lymphoblastic leukemia; CART, chimeric antigen receptor T-cell; CI, confidence interval; Cancer; Chimeric antigen receptor T cell therapy; DLBCL, diffuse large B-cell lymphoma; FDA, Food and Drug Administration; HMO, Health Maintenance Organization; ICD-10, International Classification of Disease Tenth Revision; IQR, interquartile range; NIS, National Inpatient Sample; NPD, neuropsychiatric disorders; Neuropsychiatric disorders; Neurotoxicity; OR, odds ratio; Oncology; PMBCL, primary mediastinal large B-cell lymphoma; PTSD, post-traumatic stress disorder; SE, standard error; US, United States
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article